This open-label nonrandomized phase I clinical trial was registered on clinicalTrials.gov (#NCT00472069)
Periurethral skeletal myofibre implantation in patients with urinary incontinence and intrinsic sphincter deficiency: a phase I clinical trial
Article first published online: 7 MAR 2013
© 2013 BJU International
Volume 111, Issue 7, pages 1105–1116, June 2013
How to Cite
Yiou, R., Hogrel, J.-Y., Loche, C.-M., Authier, F.-J., Lecorvoisier, P., Jouany, P., Roudot-Thoraval, F. and Lefaucheur, J.-P. (2013), Periurethral skeletal myofibre implantation in patients with urinary incontinence and intrinsic sphincter deficiency: a phase I clinical trial. BJU International, 111: 1105–1116. doi: 10.1111/j.1464-410X.2012.11682.x
- Issue published online: 9 MAY 2013
- Article first published online: 7 MAR 2013
- Assistance Publique des Hopitaux de Paris. Grant Number: 06005
- Association Française contre les Myopathies
- cell therapy;
- satellite cell;
- urinary incontinence;
- intrinsic sphincter deficiency
What's known on the subject? and What does the study add?
- Cell therapy using muscle precursor cell (MPC) injections has shown promise for urinary incontinence due to intrinsic sphincter deficiency (ISD), but the cell-preparation process is complex and costly. Implantation of freshly isolated myofibres carrying MPCs, mainly satellite cells, was very efficient in repairing muscle damage in recent animal experiments.
- In a phase I clinical trial, we investigated whether periurethral myofibre implantation generated local myogenesis and improved continence in 10 patients (five men and five women) with ISD. We found that myofibre implantation increased intraurethral pressure and periurethral electromyographic activity in patients with ISD. There were no serious side-effects.
- To assess the safety of periurethral myofibre implantation in patients with urinary incontinence due to intrinsic sphincter deficiency (ISD)
- To assess the resulting myogenic process and effects on urinary continence.
Patients and Methods
- An open-label non-randomised phase I clinical trial was conducted in five men and five women with ISD (mean age, 62.5 years).
- A free muscle strip from the patient's gracilis muscle was implanted around the urethra as a means to deliver locally myofibres and muscle precursor cells (MPCs).
- Patients were assessed for collection formation and incomplete bladder emptying.
- The maximum urethral closure pressure (MUCP) and concomitant periurethral electromyographic (EMG) activity were recorded before surgery and 1 and 3 months after surgery. Continence was assessed using the 24-h pad test and self-completed questionnaires, for 12 months.
- There were no serious side-effects.
- Continence improved significantly during the 12-month follow-up in four of the five women, including two who recovered normal continence. In the women, MUCP increased two-fold and de novo EMG periurethral activity was recorded. In the men, MUCP and EMG recordings showed similar improvements but the effect on continence was moderate.
- The few patients enrolled could affect these results.
- This is the first report of a one-step procedure for transferring autologous MPCs via myofibre implantation in patients with ISD.
- EMG and urodynamic assessments showed improvement of periurethral muscle activity.
- Further work is needed to confirm and improve the therapeutic efficiency of this procedure.